Physician profile
Rosa I Vizcarra
NPI 1649206087
$9,303.35
in general payments reported to CMS, 2019-2025
41 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 95% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $737 · 2021: $1,180 · 2022: $1,179 · 2023: $1,619 · 2024: $1,636 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,725.73 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,353.32 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,248.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,144.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $697.43 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $467.42 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $302.97 | 2022-2024 | |
| Esperion Therapeutics, INC. | $283.00 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.14 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Intuitive Surgical, INC. | $240.92 | 2019-2025 | |
| Pfizer INC. | $232.64 | 2023-2025 | |
| Abbott Laboratories | $195.25 | 2021-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $148.80 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $143.19 | 2022 | |
| Astellas Pharma US INC | $83.63 | 2019-2024 | Veozah |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74.71 | 2019-2021 | |
| Tactile Systems Technology INC | $69.94 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Amarin Pharma, INC. | $66.39 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $62.67 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $57.76 | 2019 | |
| Inspire Medical Systems, INC. | $48.25 | 2025 | Inspire |
| Angiodynamics, INC. | $37.94 | 2024 | Auryon Laser System 100-120 Vac |
| Biohaven Pharmaceuticals, INC. | $30.85 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $28.80 | 2022 | |
| Merck Sharp & Dohme LLC | $28.21 | 2019-2021 | |
| Coloplast Corp | $27.38 | 2020 | |
| Exact Sciences Corporation | $24.71 | 2023 | Cologuard Collection Kit |
| Almatica Pharma LLC | $21.58 | 2023 | Sertraline Hcl, Loreev Xr, Gralise |
| Inari Medical, INC. | $21.24 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi Pasteur INC. | $20.46 | 2023 | |
| Tris Pharma INC | $17.95 | 2024 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $15.46 | 2025 | Gemtesa |
| Medtronic, INC. | $15.32 | 2022 | |
| Antares Pharma, INC. | $15.04 | 2021 | |
| Lundbeck LLC | $14.43 | 2024 | Vyepti |
| Sanofi-Aventis U.S. LLC | $13.96 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.82 | 2019 | |
| Eisai INC. | $12.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.48 | 2022 | |
| Dynavax Technologies Corporation | $12.46 | 2024 | Heplisav-B |
| Ironwood Pharmaceuticals, INC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Vizcarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.